Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bone Marrow Grafting for Leukemia and Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00186147
Recruitment Status : Enrolling by invitation
First Posted : September 16, 2005
Last Update Posted : August 2, 2021
Sponsor:
Collaborators:
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Stanford University

Brief Summary:
The purpose of this study is to obtain tissue samples for ongoing studies regarding transplant outcomes and complications.

Condition or disease Intervention/treatment
Leukemia Lymphoma Hematologic Diseases Procedure: collection and storage of tissue samples for research

Detailed Description:
The purpose of this study is to acquire critical tissue and biological samples that can be evaluated to elucidate underlying mechanisms of disease control, transplant related complications and overall outcomes

Layout table for study information
Study Type : Observational
Estimated Enrollment : 9999 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Bone Marrow Grafting for Leukemia and Lymphoma
Study Start Date : March 1988
Estimated Primary Completion Date : December 2069
Estimated Study Completion Date : December 2069

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Graft recipients and donors Procedure: collection and storage of tissue samples for research
Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.




Primary Outcome Measures :
  1. Identify and characterize proteins and genes that may contribute to the development and progression of cancer. [ Time Frame: blood sample is collected prior transplant, periodically during the first three months and then indefinately at follow up ]

Biospecimen Retention:   Samples With DNA
Tissue samples will be obtained from subjects undergoing transplantation or donors providing the graft.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All hematopoietic cell transplant recipients and donors who agree to participate
Criteria

Inclusion Criteria:- All hematopoietic cell transplant recipients and donors who agree to participate

Exclusion Criteria:- Subject does not agree to participate


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00186147


Locations
Layout table for location information
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Investigators
Layout table for investigator information
Principal Investigator: David Miklos Stanford University
Principal Investigator: Robert S Negrin Stanford University
Layout table for additonal information
Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT00186147    
Other Study ID Numbers: IRB-08903
BMT19 ( Other Identifier: OnCore Number )
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: August 2, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Leukemia
Hematologic Diseases
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases